Chloroquinine phosphate

Suppliers

Names

[ CAS No. ]:
1446-17-9

[ Name ]:
Chloroquinine phosphate

[Synonym ]:
chloroquinone phosphate
1,4-Pentanediamine,N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-,phosphate (1:1)
Aralen phosphate
Ipsen 225
Gontochin phosphate
chloroquine phosphate
Tanakene
Miniquine
Chloroquinine phosphate
Araten phosphate

Chemical & Physical Properties

[ Boiling Point ]:
460.6ºC at 760mmHg

[ Molecular Formula ]:
C18H29ClN3O4P

[ Molecular Weight ]:
417.86700

[ Flash Point ]:
232.3ºC

[ Exact Mass ]:
417.15800

[ PSA ]:
115.73000

[ LogP ]:
3.95500

[ Vapour Pressure ]:
1.15E-08mmHg at 25°C

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
VB2625000
CAS REGISTRY NUMBER :
1446-17-9
LAST UPDATED :
199201
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C18-H26-Cl-N3.H3-O4-P
MOLECULAR WEIGHT :
417.92
WISWESSER LINE NOTATION :
T66 BNJ EMY1&3N2&2 IG &P-O4

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
43 mg/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - acute pulmonary edema
REFERENCE :
JFSCAS Journal of Forensic Sciences. (American Soc. for Testing and Materials, 1916 Race St., Philadelphia, PA 19103) V.1- 1956- Volume(issue)/page/year: 5,201,1965
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
2740 mg/kg/39W
TOXIC EFFECTS :
Behavioral - muscle weakness
REFERENCE :
ARPAAQ Archives of Pathology. (Chicago, IL) V.5(3)-50(3), 1928-50; V.70-99, 1960-75. For publisher information, see APLMAS. Volume(issue)/page/year: 93,209,1972
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
38 mg/kg
TOXIC EFFECTS :
Cardiac - other changes Lungs, Thorax, or Respiration - other changes
REFERENCE :
PEDIAU Pediatrics. (American Academy of Pediatrics, P.O. Box 1034, Evanston, IL 60204) V.1- 1948- Volume(issue)/page/year: 27,95,1961 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2660 mg/kg
SEX/DURATION :
female 2-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Effects on Newborn - other neonatal measures or effects Reproductive - Effects on Newborn - other postnatal measures or effects
REFERENCE :
AROTAA Archives of Otolaryngology. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1-52, 1925-50; V.72- 1960- Volume(issue)/page/year: 80,407,1964
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
455 mg/kg
SEX/DURATION :
female 1-13 week(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - abortion
REFERENCE :
AROTAA Archives of Otolaryngology. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1-52, 1925-50; V.72- 1960- Volume(issue)/page/year: 80,407,1964
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
420 mg/kg
SEX/DURATION :
female 1-6 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
AROTAA Archives of Otolaryngology. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1-52, 1925-50; V.72- 1960- Volume(issue)/page/year: 80,407,1964
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
25 mg/kg
SEX/DURATION :
female 18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - abortion
REFERENCE :
CCPTAY Contraception. (Geron-X, Inc., POB 1108, Los Altos, CA 94022) V.1- 1970- Volume(issue)/page/year: 31,173,1985

Safety Information

[ HS Code ]:
2933499090

Customs

[ HS Code ]: 2933499090

[ Summary ]:
2933499090. other compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Related Compounds

  • naphthyl phosphate
  • nickel phosphate
  • dibutyl phosphate anion
  • Sodium phosphate, NaH2(32)PO4
  • trisodium phosphate
  • tritetradecyl phosphate
  • N-(3,4-dimethoxyphenethyl)-3-(2-((2-((2,4-dimethoxyphenyl)amino)-2-oxoethyl)thio)-4-oxoquinazolin-3(4H)-yl)propanamide
  • 3-(7-methoxybenzofuran-2-carbonyl)-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one
  • N-(3-chloro-2-methylphenyl)-1-cyanocyclopropanecarboxamide
  • 1-((1-methyl-1H-pyrrol-2-yl)methyl)-3-(3-phenylpropyl)-1-(thiophen-2-ylmethyl)urea
  • 3-(3,4-dimethoxybenzyl)-1-((1-methyl-1H-pyrrol-2-yl)methyl)-1-(thiophen-2-ylmethyl)urea
  • 3-[6-({2-[(2,4-dimethoxyphenyl)amino]-2-oxoethyl}thio)-8-oxo[1,3]dioxolo[4,5-g]quinazolin-7(8H)-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]propanamide
  • 3-(Naphthalen-1-ylmethyl)-1-propyl-1-(thiophen-3-ylmethyl)urea
  • 3-Benzhydryl-1-propyl-1-(thiophen-3-ylmethyl)urea
  • (2-(1H-pyrrol-1-yl)thiazol-4-yl)(4-(pyridin-2-yl)piperazin-1-yl)methanone
  • N-[(2H-1,3-benzodioxol-5-yl)methyl]-4-{6-[({[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}methyl)sulfanyl]-8-oxo-2H,7H,8H-[1,3]dioxolo[4,5-g]quinazolin-7-yl}butanamide
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.